Atea Pharmaceuticals presents Phase 2 data on bemnifosbuvir and ruzasvir as potential hepatitis C treatments at AASLD 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. has presented three poster presentations...
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...
Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...
TransMedics Group TMDX is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the...
Henry Schein, Inc. HSIC is scheduled to release third-quarter 2024 results on Nov. 5, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.23,...
Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell.The company posted adjusted earnings per share (EPS) of $3.11 in the last reported...